Примери за използване на Agency noted на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The Agency noted an acceptable safety profile.
For people aged 27 through 45,only those at risk for HPV should consider getting vaccinated, the agency noted.
The Agency noted that safety profile of inhaled tobramycin was well known.
In the overall group of patients with macular oedema related to diabetes the Agency noted that the benefit was modest and was outweighed by the risks, including the development of cataracts.
The Agency noted that an on-going clinical study will provide confirmation on the long-term effectiveness.
Хората също превеждат
France, the second-largest recipient, with 47,800 applications, followed by Germany, with 41,330,also saw an increase of asylum-seekers, the UN agency noted, citing the larger number of applications from Serbia and Macedonia as one reason for that.
The agency noted in the past, common errors involved water contact with or food contacts surfaces;
With regard to safety, the Agency noted an acceptable safety profile and did not identify any substantial safety issue.
The agency noted the Greek government's fiscal consolidation programme, but cautioned that without further structural changes, this consolidation would be unsustainable in the long run.
The agency noted party politics could affect economic policy more than previously anticipated.
The Agency noted that hypophosphatasia is a serious and life-threatening disease for which no treatment is authorised.
The Agency noted the unmet medical need for patients with multiple myeloma who no longer improve with the available therapies.
The agency noted that the asteroid is presently traveling at a speed of 11.04 kilometers per second or about 25,000 miles per hour.
The Agency noted that Nplate was effective in patients who had had their spleen removed, as well as in patients who had not had their spleen removed.
The Agency noted that no medicinal product has been approved for the treatment of S-LAM and Rapamune's effect on lung function is considered important.
The Agency noted that Voncento was shown to be effective in treating and preventing bleeding in patients with haemophilia A as well as in patients with von Willebrand disease.
The Agency noted that the production of the only other vaccine for protection against Japanese encephalitis that was in use outside Asia had been discontinued.
The Agency noted that Cyramza prolonged the lives of patients with gastric and gastro-oesophageal junction cancer when it was given with paclitaxel.
The Agency noted that Nimenrix offered the benefits of conjugated vaccines over conventional vaccines, including producing a strong immune response in young children.
The Agency noted that Enurev Breezhaler had a modest but relevant benefit for patients in terms of improving lung function, and also improved the symptoms of COPD.
The Agency noted that Zelboraf had been convincingly shown to improve overall survival and to delay the worsening of‘BRAF V600 positive' melanoma which has spread or cannot be surgically removed.
The Agency noted that there is a need for an effective treatment for bone disease in advanced cancer, particularly for patients with kidney problems since currently available treatments can be toxic for the kidneys.
The Agency noted that Sustiva has not been studied adequately in patients with advanced disease(CD4 cell counts below 50 cells/mm3) or after treatment with protease inhibitors(another type of antiviral medicine) that was not working.
The Agency noted that across all studies in patients with primary hypercholesterolaemia and mixed dyslipidaemia, Repatha showed an important reduction in LDLcholesterol levels, which is a known risk factor for cardiovascular disease.
The Agency noted that inhaled tobramycin was the‘gold standard' for treating P. aeruginosa infection in patients with cystic fibrosis and that some patients cannot use the dry powder form because of unacceptable side effects.
The Agency noted the unmet need for treatments for autosomal dominant polycystic kidney disease and considered that Jinarc is effective at slowing down cyst formation and the decline in kidney function in patients with the condition.
The Agency noted that Arzerra was shown to be effective at treating patients with CLL(previously untreated patients, patients who had not responded to previous treatment with fludarabine and alemtuzumab and patients whose cancer had come back after previous treatment).
The Agency noted that, due to the small number of patients with these diseases, the information to support the authorisation of Atriance is limited, but it agreed that the medicine could allow some patients to go on to receive bone-marrow transplantation, increasing their chances of survival.
Although the Agency noted that the use of ritonavir-boosted Telzir had not been studied sufficiently in heavily pretreated patients and that studies carried out in children did not compare Telzir with a comparator medicine, it decided that Telzir's benefits are greater than its risks and it can be authorised for use in the EU.
The Agency noted that across all studies in patients with primary hypercholesterolaemia and mixed dyslipidaemia, including patients on maximum recommended doses of statins or those intolerant to them, treatment with Praluent led to a significant reduction in LDLcholesterol levels, which is a known risk factor for cardiovascular(affecting the heart and blood vessels) disease.